Navigation Links
EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models

198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, produc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
(Date:5/1/2015)... N.J., May 1, 2015 Cambrex Corporation (NYSE: ... 31, 2015. Highlights , Sales ... increased 27% excluding foreign currency impact, driven by Innovator products ... from $8.4 million in the first quarter of 2014. ... $0.04 in the first quarter last year and Adjusted Diluted ...
(Date:4/30/2015)... , April 30, 2015  Accuray Incorporated ... has signed an agreement with MIM Software Inc. ... TomoTherapy ® and CyberKnife ® product portfolios. ... and MIM technology. This is Accuray,s second collaboration ... development of the first iPad-based treatment plan review ...
(Date:4/30/2015)... -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) announced today ... after the market closes on Thursday, May 7, 2015.  ... held on Thursday, May 7, 2015, at 4:30 p.m. ... participate in the call, please dial 877-303-1298 (for U.S. ... the teleconference will be available for one week and ...
Breaking Medicine Technology:Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results 2
(Date:5/3/2015)... (PRWEB) May 03, 2015 Looking ... that will directly impact your career? The Master ... for dynamic leaders in multinational companies and for ... In a changing global landscape, differences in culture, ... relationships. The EMIB program develops the global competence ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company that ... the , May 5 - 7, 2015 Minnesota Safety ... the conference include its bestselling TaskMate sit stand solutions. ... 6100 TaskMate Executive. Features of the 6100 TaskMate Executive ... extended platform work surface and supply holders. Weighing 50 ...
(Date:5/2/2015)... 2015 “ ActOn ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... with organizations to make a difference. , In this material ... things that aren’t about money, which is why those things ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 “ Peachtree ... its monthly Tech Report, which features the latest and ... technology expert and special reporter for NewsWatch, conducted the ... high-end audio equipment. , Music is an important ... should be pampered and given the royal treatment. Peachtree ...
(Date:5/2/2015)... ZoomCare, the Portland-based innovator of on-demand healthcare announces ... new healthcare insurance to individuals and small businesses on ... is the nation’s first health insurance system built from ... Health Insurance was ZoomCare’s first such filing including rates ... review and regulation by the Oregon Insurance Division. Once ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... done on federal, state levels to combat tobacco use, ... Anti-tobacco campaigns registered some significant gains in 2007, with ... there,s still too little federal and state funding for ... their cigarette taxes. , That,s the conclusion of the ...
... David Schlotterbeck Named Vice Chairmen, DUBLIN, Ohio, Jan. ... services that improve the safety and,productivity of health care, ... of Teva North America, will join the company as,vice ... Supply Chain,Services sector., Barrett, 52, will join the ...
... With an eye to helping,customers improve their ... ) is now packing its Luxury and Ultra ... before., All Bragada Luxury mattresses will now ... the fabric. One of the softest fabrics,available for ...
... Her Battle ... with Hepatitis C, NEW YORK, Jan. ... advocating on behalf of,Americans with liver disease, is proud announce that it ... disease,including hepatitis C. To help spread the word about ALF,s work, EHE ...
... Compound Commonly Prescribed Hormone,Treatments, Use the Term "Bio-identical", ... a series of,warning letters to compounding pharmacies across ... asserted a policy that would deny hundreds of,thousands ... substituting its judgment for that of doctors. Wyeth,Pharmaceuticals, ...
... first Southern-style canned product ... American Heart Association, COLUMBUS, Ohio, Jan. 9 ... low fat and meatless, were the first,product line of ... savory,taste. Now, heart-healthy Sensibly Seasoned products also bear the ...
Cached Medicine News:Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 2Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 3Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 4Health News:Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector 2Health News:Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector 3Health News:Bragada(R) Luxury Mattress, Inc. Upgrades Luxury and Ultra Luxury Collections 2Health News:EHE International Supports the American Liver Foundation's Efforts at Raising Awareness for Hepatitis 2Health News:FDA Asserts New Policy to Restrict Women's Access to Bioidentical Hormones 2Health News:Glory Foods Receives Heart Healthy Certification 2
... test system is intended for ... of VZ IgG antibody in ... fluorescent antibody (IFA) technique. The ... a recent infection or immune ...
... The Masimo SET LNOP Blue Sensor is ... babies. The LNOP Blue sensor is ... accuracy claims for cyanotic infants and children. ... presented challenging conditions for reliable and accurate ...
Inquire...
... Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked Immunosorbent ... and quantitative determination of IgG antibody to ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
Medicine Products: